Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2001

01-04-2001 | Original Article

Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1

Authors: Merrill J. Egorin, Eleanor G. Zuhowski, D. Marc Rosen, Dorothy L. Sentz, Joseph M. Covey, Julie L. Eiseman

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2001

Login to get access
Metadata
Title
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1
Authors
Merrill J. Egorin
Eleanor G. Zuhowski
D. Marc Rosen
Dorothy L. Sentz
Joseph M. Covey
Julie L. Eiseman
Publication date
01-04-2001
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2001
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800000242

Other articles of this Issue 4/2001

Cancer Chemotherapy and Pharmacology 4/2001 Go to the issue

Original Article

In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac

Original Article

Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy

Original Article

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

Original Article

The enhancement of riboflavin-mediated photo-oxidation of doxorubicin by histidine and urocanic acid

Original Article

A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule

Original Article

Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits